Get the Stockscreener App
13.02
3.63%
-0.49
After Hours:
13.02
Eton Pharmaceuticals Inc stock is traded at $13.02, with a volume of 173.50K.
It is down -3.63% in the last 24 hours and down -15.73% over the past month.
See More
Previous Close:
$13.51
Open:
$13.52
24h Volume:
173.50K
Relative Volume:
0.63
Market Cap:
$362.30M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-50.08
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
-8.44%
1M Performance:
-15.73%
6M Performance:
+124.48%
1Y Performance:
+247.20%
1-Day Range:
$12.83
$13.64
1-Week Range:
$12.83
$15.10
52-Week Range:
$3.03
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
13.02 | 362.30M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus.com
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus.com
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - Marketscreener.com
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
(ETON) On The My Stocks Page - Stock Traders Daily
Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India
Eton Pharma rises on study results for rare disease drug - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com India
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Trading (ETON) With Integrated Risk Controls - Stock Traders Daily
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - GlobeNewswire
How Will Eton's Rare Disease Acquisitions Impact Future Growth? Investor Day Set to Reveal Strategy - StockTitan
Eton Pharmaceuticals Launches Galzin Capsules for Wilson Disease Treatment -March 03, 2025 at 11:48 am EST - Marketscreener.com
Eton Pharmaceuticals launches FDA-approved Wilson disease treatment - Investing.com
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules - GlobeNewswire
Only FDA-Approved Zinc Treatment for Wilson Disease Now AvailableWhat Makes Galzin Different? - StockTitan
60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Anchor Capital Advisors LLC - MarketBeat
(ETON) Trading Report - Stock Traders Daily
Acuitas Investments LLC Has $2.48 Million Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - MarketBeat
Insider Buying: Opaleye Management Inc., Eton Pharmaceuticals Inc [ETON] 10% Owner invested 10,000 shares - Knox Daily
What Are You Thinking About Investing In Eton Pharmaceuticals Inc (NASDAQ: ETON) Stock? - Stocks Register
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going - MSN
Learn to Evaluate (ETON) using the Charts - Stock Traders Daily
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Eton Pharmaceuticals Stock Hits All-Time High of $17.57 - MSN
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):